MedTrace Logo

A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors

NCT05169697 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-01-06

No results posted yet for this study

Summary

A multicenter, open-label, phase I dose escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YH002 in combination with YH001 in subjects with advanced solid tumors

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

A:YH002+YH001

YH002 on CnD1,YH001 on CnD8,Q3W

DRUG

B:YH002+YH001

YH002 and YH001 on same day,Q3W

DRUG

YH002+YH001

A traditional 3+3 dose escalation algorithm

Sponsors & Collaborators

  • Eucure (Beijing) Biopharma Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Hongming Pan · Sir Run Run Shaw Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-21
Primary Completion
2023-07-04
Completion
2023-07-04

Countries

  • Australia
  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05169697 on ClinicalTrials.gov